Lung Fibrosis Is Linked to Increased Endothelial Cell Activation and Dysfunctional Vascular Barrier Integrity
- 1 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 71 (3) , 318-331
Abstract
Pulmonary fibrosis (PF) can be a fatal disease characterized by progressive lung scarring. It is still poorly understood how the pulmonary endothelium is involved in the disease pathogenesis. Differences of the pulmonary vasculature between patients and donors were analyzed using transmission electron microscopy, immunohistochemistry, and single-cell RNA sequencing. Vascular barrier resistance, endothelial–immune cell adhesion, and sensitivity to an inflammatory milieu were studied in vitro. Integrity and activation markers were measured by ELISA in human plasma. Transmission electron microscopy demonstrated abnormally swollen endothelial cells (ECs) in fibrotic lungs compared with donors. A more intense CD31 and von Willebrand Factor (vWF) and patchy vascular endothelial (VE)-Cadherin staining in fibrotic lungs supported the presence of a dysregulated endothelium. Integrity markers CD31, VE-Cadherin, Thrombomodulin, and VEGFR-2 (vascular endothelial growth factor receptor-2) and activation marker vWF gene expression was increased in different endothelial subpopulations (e.g., arterial, venous, general capillary, aerocytes) in PF. This was associated with a heightened sensitivity of fibrotic ECs to TNF-α or IFN-γ and elevated immune cell adhesion. The barrier strength was overall reduced in ECs from fibrotic lungs. vWF and IL-8 were increased in the plasma of patients, whereas VE-Cadherin, Thrombomodulin, and VEGFR-2 were decreased. VE-Cadherin staining was also patchy in biopsy tissue and was decreased in plasma samples of patients with PF 6 months after the initial diagnosis. Our data demonstrate highly abnormal ECs in PF. The vascular compartment is characterized by hyperactivation and increased immune cell adhesion, as well as dysfunctional endothelial barrier function. Reestablishing EC homeostasis and function might represent a new therapeutic option for fibrotic lung diseases.Keywords
Funding Information
- German Cardio-Pulmonary Institute (390649896)
- International Foundation for Functional Gastrointestinal Disorders (34926649)
- Deutsches Zentrum für Lungenforschung (82DZL005A1)
- Deutsche Forschungsgemeinschaft (1213-Project-ID 268555672)
- Austrian Science Fund (DOC 129-B)
- German Cardio-Pulmonary Institute (390649896)
- International Foundation for Functional Gastrointestinal Disorders (34926649)
- Deutsches Zentrum für Lungenforschung (82DZL005A1)
- Deutsche Forschungsgemeinschaft (1213-Project-ID 268555672)
- Austrian Science Fund (DOC 129-B)
This publication has 53 references indexed in Scilit:
- The Vasculature in Pulmonary FibrosisCurrent Tissue Microenvironment Reports, 2022
- Idiopathic pulmonary fibrosisNature Reviews Disease Primers, 2017
- Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosisNature Medicine, 2016
- Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL‐1β, TNF‐α, and LPSCytometry Part A, 2010
- Evolving functions of endothelial cells in inflammationNature Reviews Immunology, 2007
- Nonhomogeneous Density of CD34 and VCAM-1 Alveolar Capillaries in Major Types of Idiopathic Interstitial PneumoniaLung, 2005
- ICAM-1, ICAM-2 and ICAM-3 in the Sera of Patients with Idiopathic Pulmonary FibrosisInflammation, 2004
- Increased Level of Soluble E-Selectin in the Serum from Patients with Idiopathic Pulmonary FibrosisInflammation, 2004
- Expression of the Endothelial Markers PECAM-1, vWf, and CD34 in Vivo and in VitroExperimental and Molecular Pathology, 2002
- TNF Signaling in Vascular Endothelial CellsExperimental and Molecular Pathology, 2001